Tivic health acquires exclusive worldwide rights to phase iii tlr5 agonist from statera biopharma

Fremont, calif.--(business wire)--tivic health systems, inc., (nasdaq: tivc) today announced it has acquired worldwide exclusive license rights from statera biopharma (otc: stab) to the late-stage toll-like receptor 5 (tlr5) agonist entolimod™ for the treatment of acute radiation syndrome (ars). in addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for entolimod and its derivative, entalasta™. this broad licensing agreement estab.
TIVC Ratings Summary
TIVC Quant Ranking